Cargando…

Emerging treatments for myelodysplastic syndromes: Biological rationales and clinical translation

Myelodysplastic syndromes (MDSs) are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by myeloid dysplasia, peripheral blood cytopenias, and increased risk of progression to acute myeloid leukemia (AML). The standard of care for patients with MDS is hypomethylating age...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rodriguez-Sevilla, Juan Jose, Adema, Vera, Garcia-Manero, Guillermo, Colla, Simona
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9975331/ https://www.ncbi.nlm.nih.gov/pubmed/36787738 http://dx.doi.org/10.1016/j.xcrm.2023.100940

Ejemplares similares

Safety and efficacy of azacitidine in myelodysplastic syndromes
por: Vigil, Carlos E, et al.
Publicado: (2010)

P723: CLINICAL AND MOLECULAR ASSOCIATIONS WITH OUTCOMES IN HIGHER RISK MYELODYSPLASTIC SYNDROMES TREATED WITH HYPOMETHYLATING AGENTS PLUS VENETOCLAX
por: Bazinet, Alexandre, et al.
Publicado: (2023)

Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms
por: Montalban-Bravo, Guillermo, et al.
Publicado: (2018)

P743: CLINICAL OUTCOMES OF PATIENTS WITH MYELODYSPLASTIC SYNDROME AND SPLICEOSOME MUTATIONS
por: Urrutia, Samuel, et al.
Publicado: (2023)

Response to Hypomethylating Agents in Myelodysplastic Syndrome Is Associated With Emergence of Novel TCR Clonotypes
por: Abbas, Hussein A., et al.
Publicado: (2021)

TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions
por: Daver, Naval G., et al.
Publicado: (2022)

Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy
por: Ganan-Gomez, Irene, et al.
Publicado: (2022)

Isolation, culture, and immunophenotypic analysis of bone marrow HSPCs from patients with myelodysplastic syndromes
por: Ganan-Gomez, Irene, et al.
Publicado: (2022)

Targeting the EIF2AK1 Signaling Pathway Rescues Red Blood Cell Production in SF3B1-Mutant Myelodysplastic Syndromes With Ringed Sideroblasts
por: Adema, Vera, et al.
Publicado: (2022)

Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy
por: Ganan-Gomez, Irene, et al.
Publicado: (2022)

PB2019: PHASE 1B CLINICAL STUDY OF IRAK 1/4 INHIBITION FOR LOW-RISK MYELODYSPLASTIC SYNDROMES REFRACTORY/RESISTANT TO PRIOR THERAPIES: A TRIAL IN PROGRESS
por: Garcia-Manero, Guillermo, et al.
Publicado: (2023)

Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents
por: Takahashi, Koichi, et al.
Publicado: (2016)

Emerging Therapies for the Myelodysplastic Syndromes
por: Canaani, Jonathan
Publicado: (2019)

IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression
por: DiNardo, Courtney D, et al.
Publicado: (2015)

Fidelity of peripheral blood for monitoring genomics and tumor immune‐microenvironment in myelodysplastic syndromes
por: Lee, Sung‐Eun, et al.
Publicado: (2020)

TP53 in Myelodysplastic Syndromes: Recent Biological and Clinical Findings
por: Cumbo, Cosimo, et al.
Publicado: (2020)

Fatigue, symptom burden, and health‐related quality of life in patients with myelodysplastic syndrome, aplastic anemia, and paroxysmal nocturnal hemoglobinuria
por: Escalante, Carmen P., et al.
Publicado: (2019)

P728: EVALUATION OF IPSS-M IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AND SPLICEOSOME MUTATIONS
por: Urrutia, Samuel, et al.
Publicado: (2023)

Transcriptomic analysis implicates necroptosis in disease progression and prognosis in myelodysplastic syndromes
por: Montalban-Bravo, Guillermo, et al.
Publicado: (2019)

Significant association between polymorphism of the erythropoietin gene promoter and myelodysplastic syndrome
por: Ma, Wanlong, et al.
Publicado: (2010)

The biology of myelodysplastic syndromes: unity despite heterogeneity
por: Raza, Azra, et al.
Publicado: (2010)

Improving patient understanding and outcomes in myelodysplastic syndromes - An animated patient guide to MDS with visual formats of learning
por: Sallman, David A., et al.
Publicado: (2022)

Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis
por: Komrokji, Rami S., et al.
Publicado: (2022)

P748: IPSS-M PERFORMANCE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AT THE TIME OF HYPOMETHYLATING AGENT FAILURE
por: Urrutia, Samuel, et al.
Publicado: (2023)

PB2014: A PHASE 2/3 TRIAL OF ORAL AZACITIDINE IN PATIENTS WITH LOW- OR INTERMEDIATE-RISK MYELODYSPLASTIC SYNDROMES
por: Garcia-Manero, Guillermo, et al.
Publicado: (2023)

Validation of International Working Group response criteria in higher‐risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium
por: Komrokji, Rami S., et al.
Publicado: (2020)

TET2 mutations as a part of DNA dioxygenase deficiency in myelodysplastic syndromes
por: Gurnari, Carmelo, et al.
Publicado: (2022)

Emerging Insights into Molecular Mechanisms of Inflammation in Myelodysplastic Syndromes
por: Vallelonga, Veronica, et al.
Publicado: (2023)

Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options
por: Lewis, Russell, et al.
Publicado: (2021)

Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms
por: Malcovati, Luca, et al.
Publicado: (2011)

Relative survival following response to 7+3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes:An analysis of four SWOG studies
por: Othus, Megan, et al.
Publicado: (2018)

Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: Clinical efficacy and correlative analyses
por: Konopleva, Marina, et al.
Publicado: (2023)

The Genetics of Myelodysplastic Syndromes: Clinical Relevance
por: Chiereghin, Chiara, et al.
Publicado: (2021)

Myelodysplastic syndromes
por: Hellström Lindberg, Eva
Publicado: (2018)

Myelodysplastic Syndromes with Isolated 20q Deletion: A New Clinical–Biological Entity?
por: Campagna, Alessia, et al.
Publicado: (2022)

Overexpression of the Toll-Like Receptor (TLR) Signaling Adaptor MYD88, but Lack of Genetic Mutation, in Myelodysplastic Syndromes
por: Dimicoli, Sophie, et al.
Publicado: (2013)

Accurate Detection of Uniparental Disomy and Microdeletions by SNP Array Analysis in Myelodysplastic Syndromes with Normal Cytogenetics
por: Heinrichs, Stefan, et al.
Publicado: (2009)

Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence
por: Nazha, Aziz, et al.
Publicado: (2019)

Overexpression of miR-125a in Myelodysplastic Syndrome CD34(+) Cells Modulates NF-κB Activation and Enhances Erythroid Differentiation Arrest
por: Gañán-Gómez, Irene, et al.
Publicado: (2014)

Chromothripsis Is a Recurrent Genomic Abnormality in High-Risk Myelodysplastic Syndromes
por: Abáigar, María, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_1s88d0nq56ufvel3uaumnpg3uo